JP2007500238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500238A5 JP2007500238A5 JP2006533500A JP2006533500A JP2007500238A5 JP 2007500238 A5 JP2007500238 A5 JP 2007500238A5 JP 2006533500 A JP2006533500 A JP 2006533500A JP 2006533500 A JP2006533500 A JP 2006533500A JP 2007500238 A5 JP2007500238 A5 JP 2007500238A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- administered
- per day
- ssri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 29
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 28
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 17
- 229960004341 escitalopram Drugs 0.000 claims description 17
- 229960004640 memantine Drugs 0.000 claims description 15
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 14
- 229960001653 citalopram Drugs 0.000 claims description 14
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 claims description 13
- 229950004543 neramexane Drugs 0.000 claims description 13
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 3
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 47
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 24
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 20
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical group Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- CLUKHUGGXSIGRX-UHFFFAOYSA-N methanesulfonic acid;1,3,3,5,5-pentamethylcyclohexan-1-amine Chemical group CS(O)(=O)=O.CC1(C)CC(C)(C)CC(C)(N)C1 CLUKHUGGXSIGRX-UHFFFAOYSA-N 0.000 claims 5
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229960005086 escitalopram oxalate Drugs 0.000 claims 4
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229960000584 citalopram hydrobromide Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 150000003976 azacycloalkanes Chemical class 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960000967 memantine hydrochloride Drugs 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims 1
- 150000001993 dienes Chemical class 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47363903P | 2003-05-27 | 2003-05-27 | |
| PCT/US2004/016959 WO2005000216A2 (en) | 2003-05-27 | 2004-05-27 | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500238A JP2007500238A (ja) | 2007-01-11 |
| JP2007500238A5 true JP2007500238A5 (https=) | 2009-07-30 |
Family
ID=33551455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533500A Pending JP2007500238A (ja) | 2003-05-27 | 2004-05-27 | うつ病及びその他の気分障害のために、ｎｍｄａ受容体アンタゴニストと選択的セロトニン再取り込み阻害薬の併用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20050014743A1 (https=) |
| EP (2) | EP2260844A1 (https=) |
| JP (1) | JP2007500238A (https=) |
| KR (2) | KR20070104480A (https=) |
| CN (1) | CN1794981A (https=) |
| AU (1) | AU2004251636B2 (https=) |
| CA (1) | CA2528622C (https=) |
| EA (1) | EA010430B1 (https=) |
| IL (1) | IL172163A (https=) |
| IS (1) | IS8150A (https=) |
| MX (1) | MXPA05012493A (https=) |
| NO (1) | NO20056134L (https=) |
| RS (1) | RS20050851A (https=) |
| UA (1) | UA80055C2 (https=) |
| WO (1) | WO2005000216A2 (https=) |
| ZA (1) | ZA200509542B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7086532B2 (en) * | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
| BRPI0413587A (pt) * | 2003-08-21 | 2006-10-17 | Lundbeck & Co As H | usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença |
| AR046314A1 (es) * | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| ITTO20050301A1 (it) * | 2005-05-05 | 2006-11-06 | Errekappa Euroterapici Spa | Formulazioni liquide orali contenenti citalopram |
| ZA200711123B (en) * | 2005-06-27 | 2009-08-26 | Biovail Lab Int Srl | Modified-release formulations of a bupropion salt |
| WO2007061868A2 (en) * | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| KR100769700B1 (ko) * | 2007-06-15 | 2007-10-23 | 손춘남 | 배압제거 역류방지 장치 |
| EP2548552B1 (en) * | 2007-09-12 | 2015-11-18 | Merz Pharma GmbH & Co. KGaA | Titration package for 1-amino-alkylcyclohexanes |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| JP2011520815A (ja) * | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| US8399519B2 (en) | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
| TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| IT1396556B1 (it) * | 2009-02-11 | 2012-12-14 | Serra | Uso di memantina per il trattamento di disturbi dell umore |
| WO2010126527A1 (en) * | 2009-05-01 | 2010-11-04 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| US20120123166A1 (en) * | 2009-06-29 | 2012-05-17 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US10576045B2 (en) * | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| KR20140069120A (ko) * | 2011-09-13 | 2014-06-09 | 노파르티스 아게 | S1p 수용체 조절제를 포함하는 조합물 |
| FR2983732B1 (fr) * | 2011-12-09 | 2013-11-22 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent |
| UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| KR101484405B1 (ko) * | 2013-08-14 | 2015-01-19 | 서울대학교산학협력단 | Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물 |
| KR20170013890A (ko) * | 2014-05-06 | 2017-02-07 | 노쓰웨스턴유니버시티 | Nmdar 조절 화합물의 조합물 |
| CN107847489B (zh) * | 2015-05-18 | 2021-09-17 | 森索睿翁公司 | 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂 |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| KR102089737B1 (ko) * | 2017-11-01 | 2020-03-16 | 한국화학연구원 | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES413944A1 (es) * | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
| US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
| DE69431404T2 (de) | 1993-10-22 | 2003-04-30 | Genentech Inc., San Francisco | Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe |
| CA2289190A1 (en) * | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| KR100630506B1 (ko) | 1997-06-30 | 2006-09-29 | 메르츠 파마 게엠베하 운트 코. 카가아 | Ｎｍｄａ 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법 |
| US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
| GB9802225D0 (en) * | 1998-02-02 | 1998-04-01 | Cerebrus Ltd | Chemical compounds |
| WO2000002551A2 (en) | 1998-07-13 | 2000-01-20 | Nps Pharmaceuticals, Inc. | Methods and compounds for treating depression |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| TW593223B (en) | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| EP1471909A4 (en) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| CA2529857A1 (en) * | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| WO2004056335A2 (es) * | 2002-12-23 | 2004-07-08 | Osmotica Costa Rica Sociedad Anonima | Dispositivo de liberación que contiene venlafaxina y memantina |
| AR043467A1 (es) * | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
| WO2005079756A2 (en) * | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
-
2004
- 2004-05-27 EP EP10175680A patent/EP2260844A1/en not_active Withdrawn
- 2004-05-27 KR KR1020077023390A patent/KR20070104480A/ko not_active Ceased
- 2004-05-27 CA CA2528622A patent/CA2528622C/en not_active Expired - Fee Related
- 2004-05-27 JP JP2006533500A patent/JP2007500238A/ja active Pending
- 2004-05-27 UA UAA200512522A patent/UA80055C2/uk unknown
- 2004-05-27 MX MXPA05012493A patent/MXPA05012493A/es unknown
- 2004-05-27 AU AU2004251636A patent/AU2004251636B2/en not_active Ceased
- 2004-05-27 EA EA200501867A patent/EA010430B1/ru not_active IP Right Cessation
- 2004-05-27 WO PCT/US2004/016959 patent/WO2005000216A2/en not_active Ceased
- 2004-05-27 EP EP04776170A patent/EP1631274A4/en not_active Withdrawn
- 2004-05-27 RS YUP-2005/0851A patent/RS20050851A/sr unknown
- 2004-05-27 KR KR1020057022580A patent/KR20060030469A/ko not_active Ceased
- 2004-05-27 US US10/857,597 patent/US20050014743A1/en not_active Abandoned
- 2004-05-27 CN CNA2004800143495A patent/CN1794981A/zh active Pending
-
2005
- 2005-11-24 ZA ZA200509542A patent/ZA200509542B/xx unknown
- 2005-11-24 IL IL172163A patent/IL172163A/en not_active IP Right Cessation
- 2005-11-25 IS IS8150A patent/IS8150A/is unknown
- 2005-12-22 NO NO20056134A patent/NO20056134L/no not_active Application Discontinuation
-
2009
- 2009-11-20 US US12/592,171 patent/US20100076073A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500238A5 (https=) | ||
| CA2528622A1 (en) | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | |
| US8754119B2 (en) | Use of rotigotine for the treatment of depression | |
| KR100481254B1 (ko) | 미르타자핀과하나이상의선택적인세로토닌재흡수저해제를포함하는약학조성물 | |
| EP1648433B1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| JP2017509686A5 (https=) | ||
| US20060211685A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of depression | |
| US8729120B2 (en) | Adjunctive therapy for depression | |
| RU97119427A (ru) | Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом | |
| WO2021067702A1 (en) | Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists | |
| KR102104953B1 (ko) | 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도 | |
| US6562858B2 (en) | Method for treating depression | |
| KR20210084481A (ko) | 수면 무호흡증의 치료 방법 및 조성물 | |
| ES2390225T3 (es) | Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión | |
| US6239162B1 (en) | Method for treating depression | |
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 | |
| JP6116672B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗うつ薬を含む医薬組成物 | |
| CA2590838A1 (en) | Preventive or therapeutic agent for sleep disorder | |
| KR20010099648A (ko) | 신규 조성물 | |
| JP2013510878A (ja) | 高増殖性障害を処置する組成物および方法 | |
| US20060217394A1 (en) | Treatment of anhedonia | |
| JP2009545573A (ja) | サレデュタントとおよびセロトニン再取込みの選択的阻害剤またはセロトニン／ノルエピネフリン再取込みの阻害剤とを組み合わせて含有する医薬組成物 | |
| TW200940049A (en) | Associations for obtaining medicaments for the treatment of bipolar disorders | |
| WO2004058237A1 (en) | Therapeutic use of sibutramine and analogues thereof | |
| AU2012307535A1 (en) | Combinations comprising a S1P receptor modulator |